Par Pharmaceutical Companies, Inc.™ develops, manufactures, markets and distributes high-quality pharmaceuticals through two divisions:
, our generic drug division, and
, our proprietary products division. We combine the energy and innovation of a new venture with the fully integrated resources of a leading, diversified pharmaceutical company.
Founded as a generics products company in 1978. Today includes two divisions:
- Employs more than 600 professionals in offices in Woodcliff Lake, New Jersey (Corporate Headquarters), Spring Valley, New Yor...
|09/30/14||Par Pharmaceutical Begins Shipment of Generic Exforge®|
|Woodcliff Lake, NJ, Sept. 30, 2014 – Par Pharmaceutical Companies, Inc. today announced that it has begun shipping all four strengths of amlodipine and valsartan tablets, the generic version of Novartis’ Exforge®. Par received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for amlodipine and valsartan and was granted 180 days of marketing exclusivity. Amlodipine and valsartan is indicated for the treatment of hypertension, to l... |
|09/08/14||Par Pharmaceutical Resumes Shipment of Generic Precedex® Injection|
|Woodcliff Lake, NJ, Sept. 8, 2014 – Par Pharmaceutical Companies, Inc. today announced that it has resumed shipping dexmedetomidine hydrochloride (HCl) injection, EQ 100 mcg base/mL, the generic version of Hospira’s Precedex® Injection. Par immediately resumed shipping after a U.S. District Court lifted a temporary restraining order that was issued in August at Hospira’s request. Last month, Par received final approval from the U.S. Food and Drug Administration for its Abbre... |
|08/06/14||Par Pharmaceutical Announces Quarterly Conference Call|
|Woodcliff Lake, N.J., August 6, 2014 – Par Pharmaceutical Companies, Inc. announced today that it will host a conference call on Wednesday, August 13, 2014 at 10:00 a.m. EDT to review its results of operations for the second quarter ended June 30, 2014. Par is privately held and currently makes certain financial information available to the public in its filings with the Securities and Exchange Commission. Par will file its financial statements for the quarter ended June 30, 2014 with th... |
|07/09/14||Par Pharmaceutical Begins Shipment of Fluphenazine Decanoate Injection, USP|
|Woodcliff Lake, NJ, July 9, 2014 – Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for fluphenazine decanoate injection, USP 25 mg/mL. Fluphenazine decanoate injection is a long-acting parenteral antipsychotic drug intended for use in the management of patients requiring prolonged parenteral neuroleptic therapy (e.g., chronic schizophrenics). Fluphenazine decanoate ... |
|There are currently no events scheduled.|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.